TAVO317A / Tavotek - LARVOL DELTA

A bispecific pan-γδT cell engager with IL-15 fusion that activates both δ1 and δ2 types of γδT cells for the treatment of acute myeloid leukemia (AACR 2025) - "When paired with an antibody targeting the acute myeloid leukemia (AML) associated target CD123, this bispecific pan γδ T cell engager, TAVO317A, mediated tumor cell dependent activation and degranulation of both δ1 and δ2 γδ T cells and redirected them to potently kill antigen-specific hematologic cancer cells... By recruiting both δ1 and δ2 γδ T cells, our bispecific pan γδ T cell engager can mobilize more γδ T cells that may otherwise be of limited quantity for tumor therapy. In addition, the engineered IL-15 domain for immune modulation can facilitate enhanced durability of γδ T cells in tumor cytotoxicity. Our novel proprietary bispecific pan γδ T cell engager platform has the potential to serve as a potent and efficacious alternative to CD3-based therapy by offering enhanced liquid and solid tumor immunotherapy with a better safety profile."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • CD123 • IL15 • IL2 • IL3RA